Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...

Some politicians question the future of Syrian refugees, with migration the big issue in February elections. The pact promises lower tariffs but may still meet resistance from European countries ...

A Spanish police unit is making lasting relationships with women it rescues from slavery. Don and Terri Turner were found dead in their car after heavy downpours struck Valencia in October. A new ...

Executives expressed confidence in Anaptys’ candidates in a third quarter earnings report, touting the best-in-class profile of its programs targeting the BTLA and PD-1 co-inhibitory receptors.